Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10237-10250

  Wagner, Verena ^a   Hose, Dirk ^a   Seckinger, Anja ^a   Weiz, Ludmila ^a   Meißner, Tobias ^a   Rème, Thiery ^b   Breitkreutz, Iris ^a   Podar, Klaus ^a   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a   Krämer, Alwin ^a   Klein, Bernard ^b,c   Raab, Marc S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b INSERM   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Apoptotic signaling; Mcl 1; Multiple myeloma; Survivin

Indexed keywords

BORTEZOMIB; INTERLEUKIN 6; PROTEIN MCL 1; SEPANTRONIUM BROMIDE; STAT3 PROTEIN; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; MCL1 PROTEIN, HUMAN; NAPHTHOQUINONE; TRANSCRIPTOME;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIRC5 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GENE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; RISK FACTOR; COHORT ANALYSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE; UNFOLDED PROTEIN RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COHORT STUDIES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-6; MULTIPLE MYELOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NAPHTHOQUINONES; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TRANSCRIPTOME; UNFOLDED PROTEIN RESPONSE;

EID: 84916912456     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2529     Document Type: Article

References (66)

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA and Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5):2516-2520.
2. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD, Jr., Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011; 96(1):87-95.
3. Greipp PR, Katzmann JA, O'Fallon WM and Kyle RA. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988; 72(1):219-223.
4. Zhang B, Gojo I and Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002; 99(6):1885-1893.
5. Le Gouill S, Podar K, Harousseau JL and Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell cycle. 2004; 3(10):1259-1262.
6. Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL and Anderson KC. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene. 2008; 27(6):721-731.
7. Jourdan M, De Vos J, Mechti N and Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell death and differentiation. 2000; 7(12):1244-1252.
8. Velculescu VE. Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes-SAGE and its use in global gene expression analysis. Science. 1999; 286(5444):1491-1492.
9. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nature reviews Cancer. 2008; 8(1):61-70.
10. Sarela AI, Macadam RC, Farmery SM, Markham AF and Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000; 46(5):645-650.
11. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A and Abad A. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(7):2100-2104.
12. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM and Ashfaq R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004; 100(4):751-757.
13. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2000; 6(1):127-134.
14. Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, Rossi JF, Hose D and Klein B. Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. British journal of haematology. 2009; 145(1):45-58.
15. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC and Altieri DC. An IAP-IAP complex inhibits apoptosis. The Journal of biological chemistry. 2004; 279(33):34087-34090.
16. Tulu US, Fagerstrom C, Ferenz NP and Wadsworth P. Molecular requirements for kinetochore-associated microtubule formation in mammalian cells. Current biology: CB. 2006; 16(5):536-541.
17. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A and Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell. 2004; 118(2):187-202.
18. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. British journal of haematology. 2007; 138(6):783-791.
19. Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen TC and Schonthal AH. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood. 2005; 106(13):4330-4338.
20. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP and Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002; 99(11):4079-4086.
21. Romagnoli M, Trichet V, David C, Clement M, Moreau P, Bataille R and Barille-Nion S. Significant impact of survivin on myeloma cell growth. Leukemia. 2007; 21(5):1070-1078.
22. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M and Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer research. 2007; 67(17):8014-8021.
23. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer science. 2011; 102(3):614-621.
24. Shaughnessy JD, Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109(6):2276-2284.
25. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(29):4798-4805.
26. Barlogie B, Hall R, Zander A, Dicke K and Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986; 67(5):1298-1301.
27. Schwab G, Siegall CB, Aarden LA, Neckers LM and Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991; 77(3):587-593.
28. Alvarez JV and Frank DA. Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer biology & therapy. 2004; 3(11):1045-1050.
29. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jack HM and Voll RE. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer research. 2007; 67(4):1783-1792.
30. Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, Fruehauf JH, Lin BK, Chauhan D, Hideshima T, Munshi NC, Anderson KC and Podar K. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009; 113(7):1513-1521.
31. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J and Rossi JF. Survival and proliferation factors of normal and malignant plasma cells. International journal of hematology. 2003; 78(2):106-113.
32. Podar K, Hideshima T, Chauhan D and Anderson KC. Targeting signalling pathways for the treatment of multiple myeloma. Expert opinion on therapeutic targets. 2005; 9(2):359-381.
33. Puthier D, Bataille R and Amiot M. IL-6 up-regulates mcl- 1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. European journal of immunology. 1999; 29(12):3945-3950.
34. Zhao J, Tenev T, Martins LM, Downward J and Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. Journal of cell science. 2000; 113 Pt 23:4363-4371.
35. Yang-Yen HF. Mcl-1: a highly regulated cell death and survival controller. Journal of biomedical science. 2006; 13(2):201-204.
36. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP and Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006; 107(12):4907-4916.
37. Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S and Boise LH. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011; 118(5):1329-1339.
38. Lens SM, Vader G and Medema RH. The case for Survivin as mitotic regulator. Current opinion in cell biology. 2006; 18(6):616-622.
39. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. The Biochemical journal. 2010; 430(2):199-205.
40. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A and de Bono JS. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23(4):968-973.
41. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S and Papadopoulos KP. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. 2012; 118(12):3128-3134.
42. Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG and Li F. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. International journal of biochemistry and molecular biology. 2012; 3(2):179-197.
43. Tang H, Shao H, Yu C and Hou J. Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263. Biochemical pharmacology. 2011; 82(9):1066-1072.
44. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R and Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002; 100(1):194-199.
45. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M and Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005; 19(7):1248-1252.
46. Aoki Y, Feldman GM and Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003; 101(4):1535-1542.
47. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R and Loughran TP, Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. The Journal of clinical investigation. 2001; 107(3):351-362.
48. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Loffler D, Koczan D, Thiesen HJ, Burger R, Gramatzki M and Horn F. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood. 2004; 103(1):242-251.
49. Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochemical and biophysical research communications. 2012; 425(4):711-716.
50. Townsend KJ, Zhou P, Qian L, Bieszczad CK, Lowrey CH, Yen A and Craig RW. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. The Journal of biological chemistry. 1999; 274(3):1801-1813.
51. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-681.
52. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer research. 2008; 68(9):3421-3428.
53. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD, Jr., Barlogie B, Neben K, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009; 113(18):4331-4340.
54. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Reme T, Shaughnessy JD, Jr., Barlogie B, Bertsch U, Hillengass J, Ho AD, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009; 28(44):3866-3879.
55. Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K, Reme T, Rosen-WolffA, Jauch A, Schnettler R, Ewerbeck V, Goldschmidt H, Klein B, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012; 120(5):1087-1094.
56. Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H and Hose D. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(34):4325-4332.
57. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, Bret C, Duperray C, Hose D and Klein B. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 2009; 114(25):5173-5181.
58. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, Goldschmidt H, Jauch A, Reme T, Jourdan M, Amiot M and Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011; 96(4):574-582.
59. Warren P, Taylor D, Martini PGV, Jackson J and Bienkowska J. (2007). PANP - a New Method of Gene Detection on Oligonucleotide Expression Arrays. Bioinformatics and Bioengineering, 2007 BIBE 2007 Proceedings of the 7th IEEE International Conference on, pp. 108-115.
60. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology. 2004; 3:Article3.
61. Hochberg Y and Benjamini Y. More powerful procedures for multiple significance testing. Statistics in medicine. 1990; 9(7):811-818.
62. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome biology. 2004; 5(10):R80.
63. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J and Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006; 107(7):2633-2638.
64. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Jr., Hoering A, Crowley J and Barlogie B. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 2010; 116(8):1220-1227.
65. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A and Craig RW. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer research. 1994; 54(24):6348-6352.
66. Raab MS, Breitkreutz I, Anderhub S, Ronnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, et al. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer research. 2012; 72(20):5374-5385.